Health Care·Life Sciences Tools & Services·$11.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.32 | N/A | +5.60% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.32 | N/A | +5.60% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting operational efficiency as a priority. However, they did not provide specific guidance for the future.
We are pleased with our EPS performance this quarter.
Our focus remains on maintaining operational efficiency.
Medpace's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. However, the stock reacted negatively, declining by 0.38%. The lack of revenue data and forward guidance may have contributed to investor caution.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FORTIS INC
Feb 11, 2022